Results and Data Sample Clauses

POPULAR SAMPLE Copied 1 times
Results and Data. Provider shall inform all patients, the County, and the ▇▇▇▇▇▇▇▇▇▇ County & Cities Health District of the results of each test performed.
View SourceView Similar (2)
Results and Data. Provider shall inform the affected personnel of the results of each test performed within 48-72 hours from administering each test.
View SourceView Similar (4)
Results and Data. Somanta shall be provided with, and shall have the right to access and use, all data collected or generated in the course of conducting the Clinical Trial, including, without limitation, records, reports, specimens, and other work product generated by or on behalf of any principal investigator in the course of performing the Clinical Trial, whether CONFIDENTIAL TREATMENT REQUESTED in written, graphic or electronic form or contained in any computer database or in any computer readable form ("Data"). CRICC agrees to attempt to require the principal investigator to ensure the accuracy, completeness, legibility and timeliness of all Data provided.
View SourceView Similar (2)
Results and Data. 9. Výsledky a údaje. Clinician Site and the Principal Investigator warrant that all CRFs submitted to Company will be complete and will accurately reflect the results of the Study. The parties acknowledge and agree that the data collected by Company in the performance of the Study shall be owned by Company or Sponsor, as agreed among themselves. Consistent with the terms of this Agreement, Company and Sponsor shall have the exclusive right to aggregate, deidentify and anonymize the data obtained from the Study performed pursuant to this Agreement. Clinician Site and the Principal Investigator shall have no rights in the results and data. Clinician Site shall be solely responsible for all payments due to the Principal Investigator and/or Clinician Site’s employees and/or collaborators according to the applicable law for any inventions transferred to Company or Sponsor or their designee. In any case, all data, information and documents provided to Clinician Site and the Principal Investigator by Company or Sponsor or any of their affiliates, whether in paper, oral, electronic or other form, shall remain the sole property of Company or Sponsor (and/or their affiliates), as the case may be. Klinické pracoviště a hlavní zkoušející ručí za to, že všechny záznamy subjektu hodnocení předložené společnosti budou úplné a budou přesně odrážet výsledky studie. Strany potvrzují a souhlasí s tím, že údaje shromážděné společností při provádění studie patří společnosti nebo zadavateli podle jejich vzájemné dohody. V souladu s podmínkami této smlouvy bude mít společnost a zadavatel výhradní právo k agregování, deidentifikování a anonymizování údajů získaných ze studie provedené podle této smlouvy. Klinické pracoviště a hlavní zkoušející nebudou mít žádná práva související s výsledky a údaji. Výhradní odpovědnost za všechny platby ve prospěch hlavního zkoušejícího a/nebo zaměstnanců či spolupracovníků klinického pracoviště v souladu s platnými právními předpisy nese za jakékoliv vynálezy převedené společnosti nebo zadavateli nebo jimi pověřené osobě klinické pracoviště. V každém případě zůstanou všechny údaje, informace a dokumenty poskytnuté klinickému pracovišti a hlavnímu zkoušejícímu společností nebo zadavatelem nebo přidruženými stranami, ať už písemně, ústně, elektronicky nebo jinak, výhradním majetkem společnosti nebo zadavatele (a/nebo přidružených stran), podle jejich povahy.
View Source
Results and Data. All Clinical Data shall be owned by the Party that conducts the applicable Clinical Trial. Without limiting the foregoing, any Clinical Data arising from the BeiGene Ongoing Clinical Trials (the “BeiGene Ongoing Clinical Trial Data”) shall be owned by BeiGene and included in BeiGene Know-How and the licenses granted to Novartis pursuant to Section 9.1.
View Source
Results and Data. The data and test results of research and development conducted as a result of this Agreement are confidential, proprietary and of great value to the parties. The data and test results are subject to the terms of Article X of this Agreement which are not inconsistent with this Section 11.1. ▇▇▇▇▇ ▇▇▇▇ shall not use or disclose the data or test results for any purpose other than in accordance with the terms of this Agreement. The data and test results shall be deemed to embody Technology. The data and test results shall be owned solely by ADOLOR, and ADOLOR shall be free to use the data and test results for any purpose, including but not limited to disclosure to a third party.
View Source
Results and Data. All Clinical Data shall be owned by the Party that conducts the applicable Clinical Trial. Without limiting the foregoing, any Clinical Data arising from the Initial Global Studies (other than the Novartis-Initiated Trials) and any New Registrational Clinical Trial and New Other Clinical Trial for which BeiGene is the Sponsoring Party and for which Novartis has provided a Novartis Study Design Agreement Notice (the “BeiGene Clinical Trial Data”) shall be owned by BeiGene and included in BeiGene Know-How and the Product Licenses granted to Novartis pursuant to Section 9.3.
View Source

Related to Results and Data

  • Information and Data ‌ Upon request of the Union, the Employer agrees to furnish the Union with the following information: budgets for the Board of Regents; budgets for each College; public information used in the preparation of budgets as provided by law such as salaries; minutes of meetings of the Board; policies of the Board of Regents which apply to faculty members. Voluminous information shall be made available for inspection or will be provided at reproduction cost.

  • Books, Records and Regulatory Filings (a) The Sub-Adviser agrees to maintain and to preserve for the applicable periods any such records as are required to be maintained by the Sub-Adviser with respect to the Fund by the 1940 Act and rules adopted thereunder, and by any other applicable laws, rules and regulations. The Sub-Adviser further agrees that all records that it maintains for the Fund are the property of the Fund and it will promptly surrender any of such records upon request; provided, however, that the Sub-Adviser may retain copies of such records for the applicable periods they are required by law to be retained, and thereafter shall destroy such records. (b) The Sub-Adviser agrees that it shall furnish to regulatory authorities having the requisite authority any information or reports in connection with its services hereunder that may be requested in order to determine whether the operations of the Fund are being conducted in accordance with applicable laws, rules and regulations. (c) The Sub-Adviser shall make all filings with the SEC required of it pursuant to Section 13 of the 1934 Act with respect to its duties as are set forth herein. The Sub-Adviser also shall make all required filings on Schedule 13D or 13G and Form 13F (as well as other filings triggered by ownership in securities under other applicable laws, rules and regulations) in respect of the Portfolio as may be required of the Fund due to the activities of the Sub-Adviser. The Sub-Adviser shall be the sole filer of Form 13F with respect to the Portfolio of the Fund.

  • Inspection of Property; Books and Records; Discussions (a) Keep proper books of records and account in which full, true and correct entries in conformity with GAAP and all Requirements of Law shall be made of all dealings and transactions in relation to its business and activities and (b) unless a Default or Event of Default has occurred and is continuing, not more than once a year and after at least five Business Days’ notice, (i) permit representatives of any Lender to visit and inspect any of its properties and examine and make abstracts from any of its books and records at any reasonable time to discuss the business, operations, properties and financial and other condition of the Borrower and its Significant Subsidiaries with officers and employees of the Borrower and its Significant Subsidiaries and (ii) use commercially reasonable efforts to provide for the Lenders (in the presence of representatives of the Borrower) to meet with the independent certified public accountants of the Borrower and its Subsidiaries; provided, that any such visits or inspections shall be subject to such conditions as the Borrower and each of its Significant Subsidiaries shall deem necessary based on reasonable considerations of safety and security; and provided, further, that neither the Borrower nor any Significant Subsidiary shall be required to disclose to any Lender or its agents or representatives any information which is subject to the attorney-client privilege or attorney work-product privilege properly asserted by the applicable Person to prevent the loss of such privilege in connection with such information or which is prevented from disclosure pursuant to a confidentiality agreement with third parties.

  • Background Data The Disclosing Party's Background Data, if any, will be identified in a separate technical document.

  • Data The statistical, industry-related and market-related data included in the Registration Statement and the Prospectus are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate, and such data agree with the sources from which they are derived. The Company has obtained the written consent to the use of such data from such sources to the extent necessary.